share_log

Vivos Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Vivos Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Vivos Therapeutics | S-3：特定交易注册声明
美股sec公告 ·  07/30 06:21
Moomoo AI 已提取核心信息
Vivos Therapeutics, Inc., a medical technology company based in Delaware, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024. The registration pertains to the resale of a total of 6,440,532 shares of common stock by the selling stockholder, V-CO Investors LLC, an affiliate of New Seneca Partners, Inc. This includes 169,498 shares of common stock, 3,050,768 shares issuable upon the exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon the exercise of a Common Stock Purchase Warrant. The shares were initially acquired in a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares by the selling stockholder. However, the company may receive funds if the...Show More
Vivos Therapeutics, Inc., a medical technology company based in Delaware, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024. The registration pertains to the resale of a total of 6,440,532 shares of common stock by the selling stockholder, V-CO Investors LLC, an affiliate of New Seneca Partners, Inc. This includes 169,498 shares of common stock, 3,050,768 shares issuable upon the exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon the exercise of a Common Stock Purchase Warrant. The shares were initially acquired in a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares by the selling stockholder. However, the company may receive funds if the warrants are exercised for cash. The shares are listed on The Nasdaq Capital Market under the symbol 'VVOS.' The registration statement includes details about the selling stockholder, the plan of distribution, and legal matters, excluding any personal opinions or interpretations, external information, and standard legal terms not directly related to the main event.
总部位于特拉华州的医疗技术公司Vivos Therapeutics，于2024年7月29日向证券交易委员会（SEC）提交了S-3表格登记声明。该注册申报涉及销售股票持有人V-CO Investors LLC，即New Seneca Partners，Inc的关联方，共计6,440,532股普通股的转售。这包括169,498股普通股，3,050,768股按照预先提供的认股权证行使而发行，以及3,220,266股按照普通股认股权证行使而发行。这些股票最初是在于2024年6月10日结束的定向增发募集中获得的。Vivos Therapeutics将不会从售股人出售股票中获得任何收益。但是，如果认股权证以现金行使，则公司可能会收到资金。这些股票在纳斯达克资本市场上以“VVOS”标的进行交易。该登记声明包括有关售股人、分销计划和法律事项的详细信息，不包括任何个人意见或解释、外部信息和与主要事件无直接关系的标准法律术语。
总部位于特拉华州的医疗技术公司Vivos Therapeutics，于2024年7月29日向证券交易委员会（SEC）提交了S-3表格登记声明。该注册申报涉及销售股票持有人V-CO Investors LLC，即New Seneca Partners，Inc的关联方，共计6,440,532股普通股的转售。这包括169,498股普通股，3,050,768股按照预先提供的认股权证行使而发行，以及3,220,266股按照普通股认股权证行使而发行。这些股票最初是在于2024年6月10日结束的定向增发募集中获得的。Vivos Therapeutics将不会从售股人出售股票中获得任何收益。但是，如果认股权证以现金行使，则公司可能会收到资金。这些股票在纳斯达克资本市场上以“VVOS”标的进行交易。该登记声明包括有关售股人、分销计划和法律事项的详细信息，不包括任何个人意见或解释、外部信息和与主要事件无直接关系的标准法律术语。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息